PATENT CLAIM ANALYSIS

Application Number: 15757687
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["424", "204100"]

Abstract:
The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.

Claim (Index 6):
The method of  claim 5 , wherein the oncolytic vaccinia virus is selected from the group consisting JX594 and derivatives thereof, WO-12 and derivatives thereof, the GL-ONC1 (i.e., GLV-1h68) and derivatives thereof, clonal strains of LIVP and Copenhagen, and combinations thereof.

Metadata:
- Claim Count in Document: 52.0
- Percentile: 90.0
- Lexical Diversity: 1.34884
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15892247', '14792424', '14004546', '15129916', '13470558']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7807209016060632
- 35 USC 102 Novelty (BERT): 0.5089925308993466
- Combined Prediction Score: 0.7535480645353916
- Mean Citation Score: 263.860032
- Max Citation Score: 281.17853
- Similarity Product: 195.6265260041827

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test